ストックスクリーナーアプリを入手
2.16
24.14%
0.42
アフターアワーズ：
2.11
-0.05
-2.31%
Sangamo Therapeutics Inc (SGMO) 最新ニュース
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug - MarketWatch
Sangamo stock rallies 37% on FDA update for Fabry disease drug (NASDAQ:SGMO) - Seeking Alpha
CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy - BioCentury
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) - Seeking Alpha
Cubist Systematic Strategies LLC Purchases Shares of 185,813 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Are Smart Investors Making the Right Decision? Sangamo Therapeutics Inc (SGMO) - SETE News
Sangamo Therapeutics Inc Inc. (SGMO) Price Performance: The Role of Supply and Demand - The InvestChronicle
Observations on the Sangamo Therapeutics Inc (NASDAQ:SGMO) Growth Curve - US Post News
Sangamo Therapeutics Inc (SGMO) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Sangamo Therapeutics Inc [SGMO] Investment Guide: What You Need to Know - Knox Daily
The growth track for Sangamo Therapeutics Inc (SGMO) has changed recently - SETE News
Genome Editing Market Analysis 2031, Competitive Landscape, Factors, Factors And Competition | Horizon Discovery Group, Lonza, Merck KGaA, Sangamo Therapeutics, Thermo Fisher Scientific – Times-BD24 - Times-BD24
A closer look at Sangamo Therapeutics Inc’s (SGMO) current quarter earnings projections - US Post News
Balance Sheet Breakdown: Sangamo Therapeutics Inc (SGMO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Renaissance Technologies LLC - MarketBeat
Sangamo seeks court validation for stock amendment - Investing.com India
Sangamo seeks court validation for stock amendment By Investing.com - Investing.com UK
Sangamo Therapeutics Seeks Court Approval for Stock Amendment - TipRanks
Investing in Sangamo Therapeutics Inc (SGMO) Is Getting More Attractive - Knox Daily
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India
Point72 Asia Singapore Pte. Ltd. Makes New $89,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Shares Cross Above 200-Day Moving Average of $0.64 - MarketBeat
Armistice Capital LLC Sells 2,898,477 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64 - Defense World
Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2022-2030 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews
A Tale of Resilience: Sangamo Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance
Sangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO) - MarketBeat
Press Release Service: Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex PharmaceuticalsResearchAndMarkets.comC - CRISPR Medicine News
A closer look at Sangamo Therapeutics Inc (SGMO) is warranted - US Post News
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs - MSN
Bay Area biotech company cutting 40% of workforce, closing Brisbane headquarters - MSN
Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2024- 2033 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Hemoglobinopathies Market 2024 Trend Analysis and Top Manufacturers Operating as Gamida Cell, Alnylam Pharmaceuticals, Inc, Sangamo Therapeutics – Cauverynews - Cauverynews
Genome Editing Market Worth Observing Growth: Merck KGaA, Thermo Fisher Scientific, Lonza, Sangamo Therapeutics, GenScript – Cauverynews - Cauverynews
Sangamo Therapeutics (NASDAQ:SGMO) Shares Pass Above Two Hundred Day Moving Average of $0.66 - MarketBeat
Swiss RNA maker Haya in huge licence deal - European Biotechnology News
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):